Developing a novel risk-scoring system for predicting relapse in patients with ulcerative colitis: A prospective cohort study

Pakistan Journal of Medical Sciences

Volumn 31, Issue 6, 2015, Pages 1511-1516

  Hosseini, Seyed Vahid ^a   Safarpour, Ali Reza ^b   Taghavi, Seyed Alireza ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cohort study; Prediction; Relapse; Ulcerative colitis

Indexed keywords

ALBUMIN; CALGRANULIN; IRON;

ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FAMILY HISTORY; FECES LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IRAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PATIENT HISTORY OF SURGERY; PREDICTION; PROSPECTIVE STUDY; RECURRENCE RISK; REMISSION; RISK FACTOR; SCORING SYSTEM; SEO INDEX; SEX DIFFERENCE; SMOKING HABIT; ULCERATIVE COLITIS;

EID: 84948958266     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: 10.12669/pjms.316.8811     Document Type: Article

References (25)

1. Lin L, Liu X, Wang D, Zheng C. Efficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(10):e556. doi: 10.1097/MD.0000000000000556.
2. Khalif IL, Nanaeva BA, Golovenko AO, Golovenko OV. Long-term results of medical treatment in patients with a severe attack of ulcerative colitis. Ter Arkh. 2015;87(2):34-38.
3. Vester-Andersen MK, Vind I, Prosberg MV, Bengtsson BG, Blixt T, Munkholm P, et al. Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011-a Danish population-based cohort study. J Crohns Colitis. 2014;8(12):1675-1683. doi: 10.1016/j.crohns.2014.07.010
4. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194-1201. doi: 10.1053/j.gastro.2011.06.054
5. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621-630. doi:10.1016/j.cgh.2006.03.002
6. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141(5):1621-28.e1-5. doi: 10.1053/j.gastro.2011.06.050
7. Bitton A, Dobkin PL, Edwardes MD, Sewitch MJ, Meddings JB, Rawal S, et al. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut. 2008;57(10):1386-1392. doi: 10.1136/gut.2007.134817
8. Bitton A, Sewitch MJ, Peppercorn MA, de BEMD, Shah S, Ransil B, et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol. 2003;98(10):2203-2208. doi:10.1111/j.1572-0241.2003.07717.x
9. Taghavi SA, Safarpour AR, Hoseini SV, Safarpour M, Noroozi H. Epidemiology of Inflammatory Bowel Diseases (IBD) in Iran: A review of 740 patients in Fars province, Southern Iran. Ann Colorectal Res. 2013;1(1):17-22. doi: 10.5812/acr.11477
10. Hosseini SV, Jafari P, Taghavi SA, Safarpour AR, Rezaianzadeh A, Moini M, et al. Fecal Calprotectin is an Accurate Tool and Correlated to Seo Index in Prediction of Relapse in Iranian Patients With Ulcerative Colitis. Iran Red Crescent Med J. 2015;17(2):e22796. doi: 10.5812/ircmj.22796.
11. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041-1048.
12. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120(1):13-20. doi:10.1053/gast.2001.20912
13. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold O, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006;12(7):543-550.
14. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol. 1992;87(8):971-976.
15. Walsh A, Travis S. Assessing disease activity in patients with ulcerative colitis. Gastroenterol Hepatol (N Y). 2012;8(11):751-754.
16. Jahnsen J, Roseth AG, Aadland E. Measurement of calprotectin in faeces. Tidsskr Nor Laegeforen. 2009;129(8):743-745. doi: 10.4045/tidsskr.08.0010.
17. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther. 2004;19(10):1079-1087. doi: 10.1111/j.1365-2036.2004.01945.x
18. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007;25(3):247-255. doi:10.1111/j.1365-2036.2006.03184.x
19. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005;54(3):364-368. doi: 10.1136/gut.2004.043406
20. Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014;12(11):1887-93.e3. doi: 10.1016/j.cgh.2014.03.035
21. Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, Feki M, et al. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study. Eur J Gastroenterol Hepatol. 2010;22(3):340-345. doi: 10.1097/MEG.0b013e32832bab49
22. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41(1):56-66. doi: 10.1016/j.dld.2008.05.008.
23. Nakov VN PP, Shishenkov MT, Nakov RV, Kundurzhiev TG. Fecal calprotectin for assessment of inflammatory activity, monitoring of therapy and prediction of relapse in ulcerative colitis. J GastroenterolHepatol Res. 2012;1(11):297-302. doi: 10.6051/j.issn.2224-3992.2012.01.139
24. Jang ES, Lee DH, Kim J, Yang HJ, Lee SH, Park YS, et al. Age as a clinical predictor of relapse after induction therapy in ulcerative colitis. Hepatogastroenterology. 2009;56(94-95):1304-1309.
25. Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011;17(3):194-198. doi: 10.4103/1319-3767.80383.